Haemonetics (NYSE:HAE) Hits New 12-Month High – Here’s Why

Haemonetics Corporation (NYSE:HAE)’s share price hit a new 52-week high during trading on Wednesday. The company traded as high as $125.38 and last traded at $124.78, with a volume of 42,324 shares trading hands. The stock had previously closed at $120.28.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported Q2 revenue of $357.8 million, up 9.4% year over year and above the roughly $345.2 million consensus. EPS of $1.35 also beat estimates of $1.29, showing stronger-than-expected quarterly performance. Haemonetics Q2 results and outlook
• Positive Sentiment: The company raised its fiscal 2027 revenue outlook and outlined expected organic growth of 6%–9%. It also plans to scale the CSL Persona PLUS rollout through calendar 2027, providing a potential growth opportunity. FY 2027 growth outlook and CSL rollout
• Positive Sentiment: BTIG raised its price target to $142 from $130 and reiterated a Buy rating, reflecting a more favorable analyst view. Shares were also reported at a fresh 52-week high, although that may mean some optimism is already reflected in the price.
• Neutral Sentiment: The earnings-call coverage highlighted tradeoffs between growth and margins. Investors will look for details on whether the growth initiatives and product rollout can translate into sustained profitability. Earnings-call highlights

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on HAE. Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Barrington Research upped their price objective on Haemonetics from $118.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. BTIG Research increased their target price on Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a research report on Thursday. JPMorgan Chase & Co. increased their target price on Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Finally, Mizuho set a $165.00 target price on shares of Haemonetics in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average target price of $114.11.

Haemonetics Trading Down 3.3%

The stock has a market cap of $5.60 billion, a P/E ratio of 60.38, a P/E/G ratio of 2.55 and a beta of 0.63. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The stock’s fifty day moving average is $111.18 and its 200 day moving average is $79.80.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The company had revenue of $357.76 million for the quarter, compared to analysts’ expectations of $345.15 million. During the same period in the previous year, the firm posted $1.27 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. As a group, equities research analysts predict that Haemonetics Corporation will post 5.29 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds and other institutional investors have recently bought and sold shares of HAE. Dimensional Fund Advisors LP grew its stake in Haemonetics by 21.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after purchasing an additional 233,119 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Haemonetics by 1,191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after purchasing an additional 418,470 shares in the last quarter. Bank of America Corp DE bought a new stake in Haemonetics during the 2nd quarter valued at $33,326,000. William Blair Investment Management LLC purchased a new stake in shares of Haemonetics in the 2nd quarter worth $24,906,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Haemonetics in the 2nd quarter worth $21,566,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.